Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Queensland Health
Federal Trade Commission
Deloitte
Colorcon
Express Scripts
Accenture
Dow
Teva
QuintilesIMS

Generated: January 16, 2018

DrugPatentWatch Database Preview

REQUIP Drug Profile

« Back to Dashboard

Which patents cover Requip, and when can generic versions of Requip launch?

Requip is a drug marketed by Glaxosmithkline Llc and is included in two NDAs. There are two patents protecting this drug and nine Paragraph IV challenges.

The generic ingredient in REQUIP is ropinirole hydrochloride. There are fourteen drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the ropinirole hydrochloride profile page.

US Patents and Regulatory Information for REQUIP

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-001 Sep 19, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-006 Apr 10, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-005 Oct 31, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-005 Sep 19, 1997 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-004 Sep 19, 1997 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-002 Jun 13, 2008 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-004 Jun 13, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-001 Jun 13, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-006 Apr 10, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-003 Jun 13, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for REQUIP

Paragraph IV (Patent) Challenges for REQUIP
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 3 mg ➤ Subscribe 1/8/2009
➤ Subscribe Extended-release Tablets 6 mg ➤ Subscribe 7/22/2009
➤ Subscribe Extended-release Tablets 12 mg ➤ Subscribe 2/5/2009
➤ Subscribe Extended-release Tablets 3 mg ➤ Subscribe 1/8/2009
➤ Subscribe Extended-release Tablets 8 mg ➤ Subscribe 11/3/2008
➤ Subscribe Extended-release Tablets 4 mg ➤ Subscribe 10/31/2008
➤ Subscribe Extended-release Tablets 2 mg ➤ Subscribe 10/14/2008
➤ Subscribe Tablets 3 mg, 4 mg and 5 mg ➤ Subscribe 2/4/2005
➤ Subscribe Tablets 0.25 mg, 0.5 mg, 1 mg and 2 mg ➤ Subscribe 12/22/2004

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Chubb
Express Scripts
Healthtrust
Cipla
Merck
QuintilesIMS
US Army
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot